In AD, the analysis of cerebrospinal fluid (CSF) biomarkers (with a typical pattern of elevated tau, phosphorylated tau [phospho-tau] and decreased beta-amyloid 42 [Aβ42]) is an acknowledged and promising tool in the diagnosis of Alzheimer’s disease [9]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.